| Date | Title | Description |
| 03.09.2026 | HEOR Services Market to Reach $7.9 Billion as Payers Demand Stronger Evidence on Treatment Value | Rockville, Maryland, United States – September 3, 2026 — The U.S. Centers for Medicare & Medicaid Services selected 15 high-cost Medicare Part B and Part D drugs for the third cycle of Medicare drug price negotiations in January 2026, b... |
| 15.05.2026 | Syneos Health Expands Strategic AI Partnerships to Advance Commercial Precision Performance | announced new and expanded strategic partnerships that strengthen its cutting-edge, AI ecosystem. These innovative solutions represent best-in-breed technologies that help biopharma companies deepen healthcare provider (HCP) engagement and ... |
| 07.05.2026 | MedTech Breakthrough Announces 2026 Award Winners: Celebrating a Decade of Health Technology Innovation | What You Should Know
MedTech Breakthrough has announced the winners of its 10th annual awards program, recognizing excellence in digital health and medical technology across more than 20 countries.
The 2026 awards highlight a decade of evol... |
| 02.04.2026 | Telix Appoints David Gill as Non-Executive Director | MELBOURNE, Australia and INDIANAPOLIS, April 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board ... |
| 26.06.2025 | Redefining Early Phase Oncology: What Project Optimus Means for You, Upcoming Webinar Hosted by Xtalks | www.syneoshealth.com/
In this free webinar, learn what early FDA engagement looks like under Project Optimus — and how to get it right. Attendees will gain insight into why 3+3 is out — and what smarter, regulator-ready models look like. Th... |
| 23.04.2025 | From Fragmentation to Integration: How Unified Technology Transforms Site Efficiency, Upcoming Webinar Hosted by Xtalks | www.studykik.com
In this free webinar, learn why a cohesive technological approach is essential for addressing current challenges in clinical research and how it can reduce burdens on research sites. Attendees will gain insight into the mos... |
| 01.04.2025 | How AI is Revolutionizing Drug Safety Case Intake: Boosting Accuracy, Efficiency & Expertise, Upcoming Webinar Hosted by Xtalks | www.syneoshealth.com
In this free webinar, gain insight into the end-to-end workflow of a drug safety tool from intake to database integration. Attendees will learn about the time savings that can be achieved by implementing AI in case proc... |
| 26.03.2025 | Rethinking Recruitment and Retention with Empathy and Innovation: What if Patients Chose You? Upcoming Webinar Hosted by Xtalks | www.studykik.com
In this free webinar, learn about leveraging technology that prioritizes patient's needs and creates a seamless and personalized experience. Attendees will learn how tech solutions can simplify patient outreach, enhance com... |
| 18.10.2024 | Red Nucleus Receives Majority Investment from THL Partners | Red Nucleus, a Yardley, PA-based provider of strategic services across research and development, medical affairs, market access, and learning and development, medical affairs, market access, and learning and development, received a majority... |
| 17.10.2024 | REMS Technology Innovation: Reducing Prescriber and Pharmacy Burden, Upcoming Webinar Hosted by Xtalks | www.syneoshealth.com
In this free webinar, learn how risk evaluation and mitigation strategy (REMS) industry partners are collaborating to utilize health information technology standards to simplify REMS program implementations and reduce s... |
| 04.10.2024 | Iona Star LP announces £22M first close of new AI and data fund | AI and data venture capital fund Iona Star LP has announced the successful £22 million first close of its new fund.
The Fund has received financial backing of £10 million from Castelnau Group, and £10 million from retailer Frasers Group, wh... |
| 19.09.2024 | Multi-sponsor Pregnancy Exposure Registries: Physician, Scientific Advisory and Industry Insights, Upcoming Webinar Hosted by Xtalks | www.syneoshealth.com
In this free webinar, learn how pregnancy exposure registries are helping in assessing medication safety and thus enhance pregnancy safety studies. Attendees will learn about the historical context of single- vs multi-s... |
| 18.09.2024 | The Evolution of Oncology: A New Era in Cancer Treatment | The landscape of oncology is changing. Rapid advancements in drug development are reshaping how we approach cancer treatment. The recent European Society for Medical Oncology (ESMO) 2024 annual meeting showcased this transformation. The spo... |
| 18.09.2024 | Transforming Oncology Drug Development: Insights from Healthcare Providers on the Frontlines of Cancer Care, Upcoming Webinar Hosted by Xtalks | www.syneoshealth.com
In this free webinar, learn how new data unveiled at the European Society for Medical Oncology (ESMO) 2024 annual meeting may impact the future of cancer treatment. Attendees will review the status of current antibody-d... |
| 18.09.2024 | FINN Partners Appoints Julie Adrian for Growing Agency’s UK Health Group | FINN Partners, one of the world’s leading independent marketing and communications agencies, today announces the appointment of Julie Adrian as Managing Partner and UK Health Group Lead. In the newly created position, Adrian reports to Gil ... |
| 11.09.2024 | From Extra to Essential: Scaling Mobile Apps for Future-Proofed Patient Engagement and Universal Sponsor Adoption, Upcoming Webinar Hosted by Xtalks | www.studykik.com
In this free webinar, learn about embracing forward-thinking approaches to patient engagement and retention. Attendees will learn about shifting from reactive to proactive promises to drive profound industry-wide impact. Th... |
| 11.09.2024 | Cure® Announces 2024 XSeed Award Winners, Promoting Women- and Minority-Led Life Science Startups in New York City | Teams led by Carol M. Troy, MD, PhD, of Columbia University Medical Center, and Paraskevi Giannakakou, PhD, of Weill Cornell Medical College, each to receive $250,000 grants
NEW YORK, Sept. 11, 2024 /PRNewswire/ -- Cure, a premier healthcar... |
| 04.09.2024 | Blue Matter Hires New Principal, John Bonasera, Expanding Capabilities in Organizational Strategy and Effectiveness | NEW YORK, Sept. 4, 2024 /PRNewswire/ -- Blue Matter is pleased to announce that it has hired John Bonasera as a Principal in its New York office. John officially joined the firm on September 3 and will play a key role in helping to expand t... |
| 16.07.2024 | Adapt or Fall Behind: Mastering the Inflation Reduction Act's Impact on Biopharmaceutical Market Access, Upcoming Webinar Hosted by Xtalks | www.syneoshealth.com
In this free webinar, learn about the new compliance requirements and regulatory adjustments under the Inflation Reduction Act (IRA). Attendees will discover strategic planning techniques to drive innovation while maint... |
| 19.06.2024 | From Insight to Impact: Leveraging Early Medical Affairs Engagement for Future Commercial Success, Upcoming Webinar Hosted by Xtalks | www.syneoshealth.com
In this free webinar, learn the importance of early medical affairs engagement. Attendees will learn how to prioritize tactics that maximize value within constrained budgets, ensuring that every dollar spent contributes... |
| 23.05.2024 | Spectrum Science CEO Jonathan Wilson Appoints Amy Hutnik as President | Spectrum Science, a full-service strategic platform offering integrated engagement, retention, marketing, communications and advisory services for the health and life science industries, today announced the appointment of Amy Hutnik to the ... |
| 16.05.2024 | Medical Science Liaisons Deal in the Currency of Information: How Are You Cashing In? Upcoming Webinar Hosted by Xtalks | www.syneoshealth.com
In this free webinar, understand how medical science liaisons (MSLs) can strategically engage with diverse stakeholders to gather valuable insights that inform medical strategy and drive development decisions. Attendees... |
| 08.04.2024 | Planning for the Payer: Clinical Trial Design Considerations for Today's Access & Reimbursement Landscape, Upcoming Webinar Hosted by Xtalks | www.syneoshealth.com
In this free webinar, learn about the critical role of payers as stakeholders in clinical trial design. Attendees will learn the key proof points in clinical programs essential for reimbursement success. The featured sp... |
| 26.03.2024 | Navigating Patient Payments in the Digital Era, Upcoming Webinar Hosted by Xtalks | www.studykik.com
In this free webinar, learn about the evolving landscape of patient payments and its implications for trial management. Attendees will gain insights into leveraging digital platforms for streamlined participant payment proc... |
| 25.03.2024 | Veeva Vault EDC Surpasses 1,000 Study Start Milestone | Eight of the top 20 biopharmas standardize on Vault EDC to build a modern clinical data foundation
SINGAPORE, March 25, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva Vault EDC powered more than 1,000 study start... |
| 12.03.2024 | Real World Evidence/RWE Solutions Market is growing at a CAGR of 13.8% from 2024 to 2030 by Exactitude Consultancy | Real World Evidence (RWE) Solutions market
The Exactitude Consultancy Real World Evidence/RWE Solutions Market Report – Size, Trends, and Forecast 2024-2030
The Real World Evidence (RWE) Solutions market is experiencing high demand due to i... |
| 26.06.2023 | The Three Perils of Cross-Functional Drug Commercialization — Time, Insight and Integration, Upcoming Webinar Hosted by Xtalks | In this era of accelerated drug development, understanding the challenges of time, insight and integration is key to achieving commercial success.
TORONTO (PRWEB) June 26, 2023
Marketing and commercialization are not individual functions, b... |
| 31.05.2023 | How Eligibility Review Can Enhance Clinical Trial Outcomes, Upcoming Webinar Hosted by Xtalks | Measures that help improve clinical trial outcomes by increasing the likelihood of a clear, interpretable signal and avoiding unnecessary trial failure are therefore of great potential value.
TORONTO (PRWEB) May 31, 2023
Clinical trials hav... |
| 26.05.2023 | FivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos Health | Supporting FivepHusion's Global Development and Commercialization Strategy
SYDNEY, May 26, 2023 /PRNewswire/ -- FivepHusion, an advanced clinical-stage biotechnology company, today announced its collaboration with Treehill Partners, a New Y... |
| 25.05.2023 | Syneos Health Appoints Batisha Anson to Global Head, Patient Diversity and Health Equity | Newly Created Role Demonstrates Commitment to Improve Diversity in Clinical Trials and Commercialization Across Organization
/EIN News/ -- MORRISVILLE, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully int... |
| 22.05.2023 | Participant Engagement and Realities in Decentralized Clinical Trials, Upcoming Webinar Hosted by Xtalks | How can the feedback from participants in recent clinical trials help industry refine its decentralized clinical trial (DCT) approach to be even more inclusive and responsive to patient preferences?
TORONTO (PRWEB) May 22, 2023
Today’s clin... |
| 17.05.2023 | Syneos Health Leaders Recognized by HBA | Healthcare Businesswomen’s Association Spotlights Jennifer Sozio and Caitlin Purinai for Biopharma Industry Impact
/EIN News/ -- MORRISVILLE, N.C., May 17, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated b... |
| 25.04.2023 | New Opportunities for Value Creation: How Biotechs Can Succeed in an Increasingly Competitive Market, Upcoming Webinar Hosted by Xtalks | The featured speakers will discuss strategic and operational implications for the biotech C-suite and share perspectives on how companies can succeed in an increasingly competitive environment.
TORONTO (PRWEB) April 25, 2023
The game has ch... |
| 13.04.2023 | Syneos Health Schedules First Quarter 2023 Earnings Call for Wednesday, May 10th, 2023 | /EIN News/ -- MORRISVILLE, N.C., April 13, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, will release its first quarter 2023 financial results on Wednesday, May 1... |
| 05.04.2023 | ESG: Creating Greener Clinical Trials, Upcoming Webinar Hosted by Xtalks | The world is moving towards a greener economy — meaning that investors, financial institutions and the general public all want to see evidence of ESG activities associated with the money they make available to organizations.
TORONTO (PRWEB)... |
| 24.03.2023 | Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 24th March 2023 | This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human-s... |
| 23.03.2023 | Syneos Health and KX Partner to Pioneer Data-Driven Transformation in Biopharmaceutical Asset Development | Collaboration Will Leverage Data Analytics and AI to Accelerate Clinical Trial Execution
Syneos Health, a leading fully integrated biopharmaceutical solutions organization, announced a strategic partnership with KX, maker of kdb, the world’... |
| 22.03.2023 | Thinking Differently About Indication Prioritization: Considerations for Making Better Strategic Decisions, Upcoming Webinar Hosted by Xtalks | But markets are changing at warp speed. There is a need to be more asset-focused and forward-looking when evaluating indication opportunities.
TORONTO, Ontario, Canada (PRWEB) March 22, 2023
The direction of an asset coming out of discovery... |
| 28.02.2023 | StudyKIK Awarded SCOPE Participant Engagement Award for Oncology Study Application and Best of Show for Patient Payment Platform, StudyCash | “We couldn't be more thrilled that StudyKIK's passion for excellence and drive to make a difference in the industry was acknowledged. It’s validation of our mission to transform the study experience with innovative, empathetic and thoughtfu... |
| 08.02.2023 | Syneos Health Partners with Equicare, Optimizing Data Capture and Integration to Accelerate Clinical Trial Research | /EIN News/ -- MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Equicare to use proXimity™, an... |
| 07.02.2023 | Syneos Health and Haystack Health Partner to Accelerate Clinical Trials with AI | Combined Capabilities Will Help Improve Trial Lifecycles for Patients, Sites & Sponsors
/EIN News/ -- MORRISVILLE, N.C., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), the only fully integrated biopharmaceutical soluti... |
| 09.01.2023 | Syneos Health Announces Chief Financial Officer Transition | Reaffirms Full-Year 2022 Revenue Guidance
/EIN News/ -- MORRISVILLE, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that, effective ... |
| 05.01.2023 | Importance of Early Integrated Evidence Strategy for Cell & Gene Therapies, Upcoming Webinar Hosted by Xtalks | An integrated, cross-functional evidence strategy can ensure that the right processes, tools, culture, governance and training are available to support evidence generation and evidence dissemination activities.
TORONTO (PRWEB) January 05, 2... |
| 03.01.2023 | Syneos Health to Present at the 41st Annual J.P. Morgan Healthcare Conference | /EIN News/ -- MORRISVILLE, N.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe is scheduled to... |
| 21.11.2022 | Building Next: 3 Ways to Respond to Shifts in Healthcare Realities in 2023 and Beyond, Upcoming Webinar Hosted by Xtalks | The featured speakers will discuss and apply interactive activities to each, with the goal of leaving attendees more confident in their ability to build their next — the future.
TORONTO (PRWEB) November 21, 2022
It’s not easy to plan for a ... |
| 04.11.2022 | Syneos Health Reports Third Quarter 2022 Results | Revenue for the third quarter of $1,336.2 million decreased 0.9% on a reported basis and increased 2.2% on a constant currency basis year-over-year.
Clinical Solutions net new business awards and book-to-bill ratios:
Including reimbursable ... |
| 21.10.2022 | Syneos Health Schedules Third Quarter 2022 Earnings Call for Friday, November 4, 2022 | /EIN News/ -- MORRISVILLE, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2022 financial results on Friday, November 4... |
| 21.10.2022 | Syneos Health Schedules Third Quarter 2022 Earnings Call for Friday, November 4, 2022 | MORRISVILLE, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2022 financial results on Friday, November 4, 2022, prior ... |
| 17.10.2022 | Digital health news, funding round up in the prior week; October 17, 2022 | Rite Aid partnered with Google Cloud; Walgreens bought CareCentrix; Brave Health raised $40M
Top Health News
PointClickCare Technologies, a healthcare technology platform enabling collaboration and access to real‐time insights, announced th... |
| 14.10.2022 | Syneos Health Appoints William E. Klitgaard Independent Director | /EIN News/ -- MORRISVILLE, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of William E. Klitgaard to its Board of Di... |
| 14.10.2022 | Syneos Health Appoints William E. Klitgaard Independent Director | MORRISVILLE, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of William E. Klitgaard to its Board of Directors. Mr. K... |
| 13.10.2022 | Using Tech-Enabled Solutions to Amplify Diverse Clinical Trial Recruitment, Upcoming Webinar Hosted by Xtalks | With more than 2000 industry CEOs joining the CEO Action for Diversity & Inclusion Pledge, diversity in clinical trial recruitment has emerged as both a business and human priority.
TORONTO (PRWEB) October 13, 2022
The persistent lack o... |
| 13.10.2022 | Syneos Health Wins Triangle Business Journal 2022 Leaders in Diversity Award | MORRISVILLE, N.C., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has been awarded a Triangle Business Journal 2022 Leaders in Diversity... |
| 12.10.2022 | Getting Your Asset into the Global Market: Regulatory, Clinical and Commercial Considerations, Upcoming Webinar Hosted by Xtalks | There is therefore a growing need to re-evaluate trial design strategies to not only meet approval requirements, but also drive product market uptake and overall commercial success.
TORONTO (PRWEB) October 12, 2022
Despite recession risk, g... |
| 11.10.2022 | Syneos Health Expands Partnership with Datavant to Accelerate Delivery of New Therapies to Patients | MORRISVILLE, N.C., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced an expanded partnership with Datavant, the leader in helping organization... |
| 05.10.2022 | Syneos Health Releases Annual Sustainability Report | MORRISVILLE, N.C., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 2021 Sustainability Report. The Report spotlights how the Company and ... |
| 04.10.2022 | Placebo Response Mitigation Strategies & Tools for Optimizing Clinical Trials, Upcoming Webinar Hosted by Xtalks and Syneos Health | Applying these prognostic covariates significantly decrease the data variability and consequently improve the statistical analysis reducing the risk of trial failure.
TORONTO (PRWEB) October 04, 2022
This webinar will review available metho... |
| 21.09.2022 | Guerbet Announces U.S. Food and Drug Administration (FDA) Approval of Elucirem™ (Gadopiclenol) Injection for Use in Contrast-Enhanced MRI | Elucirem™ has the highest relaxivity compared to other non-specific GBCAs 1 Elucirem™ requires only half the gadolinium dose of conventional non-specific GBCAs Elucirem™ will be manufactured in Raleigh, North Carolina by Liebel-Flarsheim™ C... |
| 30.08.2022 | Syneos Health to Present at the 2022 Baird Global Healthcare Conference | MORRISVILLE, N.C, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe and Chief Financial Officer Ja... |
| 22.08.2022 | Digital health news, funding roundup in the prior week; August 22, 2022 | The CDC restructures; AliveCor raises new funding; Caregility integrates with Eko
Top Health News
Telehealth provider Caregility partnered with smart stethoscope platform Eko. The partnership with Caregility integrates Eko Connect, Eko’s su... |
| 11.08.2022 | Preparing and Aligning Your Biotech Organization for Commercial Success, Upcoming Webinar Hosted by Xtalks | As emerging biotech companies find the right path to commercialization for their organization, there are key questions to consider when determining if your organization is aligned for commercial success
TORONTO (PRWEB) August 11, 2022
An em... |
| 02.08.2022 | Syneos Health Reports Second Quarter 2022 Results | Revenue for the second quarter of $1,360.7 million increased 6.1% on a reported basis and 8.3% on a constant currency basis year-over-year.
Clinical Solutions net new business awards and book-to-bill ratios:
Including reimbursable out-of-po... |
| 18.07.2022 | Syneos Health Schedules Second Quarter 2022 Earnings Call for Tuesday, August 2, 2022 | MORRISVILLE, N.C., July 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its second quarter 2022 financial results on Tuesday, August 2, 2022, prior ... |
| 29.06.2022 | Patient Engagement in the Digital Age: Leveraging Technology to Improve Communication Between Patients and Stakeholders, Upcoming Webinar Hosted by Xtalks | To make this customer-centric framework a sustainable reality, ongoing challenges impacting participant recruitment and retention in clinical trials must be addressed.
TORONTO (PRWEB) June 29, 2022
Shifting expectations in the healthcare in... |
| 14.06.2022 | Next-Gen Cell Therapies: Listening and Engaging with Patient Perspectives as an Essential Element in Clinical Trials, Upcoming Webinar Hosted by Xtalks | How can we continue to get closer to meeting and beating the real-world expectations of patients and caregivers, and ensure we stay one step ahead of the heightened expectations of regulators, payers and customers?
TORONTO (PRWEB) June 14, ... |
| 26.05.2022 | Are You Ready for EU CTR? The Challenges, Lessons Learned and Innovations Surrounding the New Regulation, Upcoming Webinar Hosted by Xtalks | Companies wanting to run future interventional medicinal trials in the EU now more than ever need to ensure that their readiness programs are prioritized.
TORONTO (PRWEB) May 26, 2022
The European Union Clinical Trial Regulation (EU CTR) is... |
| 24.05.2022 | Syneos Health to Present at Upcoming Investor Conferences | MORRISVILLE, N.C., May 24, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, announced that the Company is scheduled to present at two upcoming investor conferences. C... |
| 10.05.2022 | Syneos Health Leaders Recognized by HBA | MORRISVILLE, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Kasey Boynton, MPH, MBA, Director, Client Engagement, Real World Evid... |
| 29.04.2022 | Syneos Health Names Michelle Keefe as Next Chief Executive Officer | Alistair Macdonald to Retire After 20 Years in Variety of Leadership Roles
Michael Brooks Named Chief Operating Officer
Company Reports First Quarter 2022 Results and Updates Full Year Guidance
MORRISVILLE, N.C., April 29, 2022 (GLOBE NEWSW... |
| 29.04.2022 | Syneos Health Reports First Quarter 2022 Results | Highlights
Revenue for the first quarter of $1,336.3 million increased 10.5% on a reported basis and 11.7% on a constant currency basis year-over-year.Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursabl... |
| 19.04.2022 | Syneos Health Promotes Baba Shetty to President, Technology and Data Solutions, and Suma Ramadas to Executive Vice President, Medical Affairs | MORRISVILLE, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the promotions of two senior internal leaders – Baba Shetty to President... |
| 11.04.2022 | Syneos Health Schedules First Quarter 2022 Earnings Call for Friday, April 29th, 2022 | MORRISVILLE, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, will release its first quarter 2022 financi... |
| 17.02.2022 | Syneos Health Reports Fourth Quarter and Full Year 2021 Results | Highlights Fourth quarter revenue of $1,373.4 million increased 20.5% year-over-year.Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $357.1 million for the fourth quarter, a... |
| 03.02.2022 | Connections Health Solutions Expands Leadership Team | PHOENIX, Feb. 3, 2022 /PRNewswire/ -- Connections Health Solutions, the founder and national leader of immediate-access behavioral health crisis stabilization, announced additions to the leadership team and the board of directors to support... |
| 01.02.2022 | Syneos Health Schedules Fourth Quarter and Full Year 2021 Earnings Call for Thursday, February 17th, 2022 | MORRISVILLE, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, will release its fourth quarter and full yea... |
| 26.01.2022 | Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada | Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada
Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant ... |
| 18.01.2022 | Syneos Health Appoints Two New Independent Directors | MORRISVILLE, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has appointed two new independent directors, Barbara W. Bodem and Alfo... |
| 11.01.2022 | Syneos Health Releases 2022 Dealmakers’ Intentions Survey | MORRISVILLE, N.C., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 12th annual Dealmakers’ Intentions Survey. Conducted on an annual basi... |
| 11.01.2022 | Syneos Health Releases 2022 Dealmakers' Intentions Survey | MORRISVILLE, N.C., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 12th annual Dealmakers’ Intentions Survey. Conducted on an annual basi... |
| 04.01.2022 | Syneos Health to Present at the 40th Annual J.P. Morgan Healthcare Conference | MORRISVILLE, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, today announced that Chief Executive Officer... |
| 21.12.2021 | Syneos Health Releases 2022 Health Trends | New Era of Biopharma Product Development to be Fueled by Value Creation, Human Centricity and Industry Change
MORRISVILLE, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical sol... |
| 21.12.2021 | Syneos Health Releases 2022 Health Trends | MORRISVILLE, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released 2022 Health Trends: Insights for Industry Change Agents. From patient-powe... |
| 11.11.2021 | Syneos Health to Present at Upcoming Investor Conferences | MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that the Company is scheduled to present at two upcoming investor confere... |
| 03.11.2021 | Syneos Health Reports Third Quarter 2021 Results | Highlights Third quarter revenue of $1,348.2 million increased 22.7% year-over-year.Clinical Solutions net new business awards of $1,353.8 million for the third quarter, representing year-over-year growth of 35.0% and a book-to-bill ratio o... |
| 03.11.2021 | Syneos Health Reports Third Quarter 2021 Results | Highlights Third quarter revenue of $1,348.2 million increased 22.7% year-over-year.Clinical Solutions net new business awards of $1,353.8 million for the third quarter, representing year-over-year growth of 35.0% and a book-to-bill ratio o... |
| 19.10.2021 | Syneos Health Schedules Third Quarter 2021 Earnings Call for Wednesday, November 3rd, 2021 | MORRISVILLE, N.C., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2021 financial results on Wednesday, November 3rd, 2021, p... |
| 06.10.2021 | Syneos Health Acquires RxDataScience | MORRISVILLE, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the acquisition of RxDataScience, a leading healthcare-focused data analy... |
| 22.07.2021 | Optimizing Your Site Contracting and Payment Approach in a Post-Pandemic World, Upcoming Webinar Hosted by Xtalks | Significant concessions have been made by both sponsors and sites during the pandemic; some will become norms while others will be rolled back or altered to fit within the new clinical development paradigm going forward.
TORONTO (PRWEB) Jul... |
| 24.06.2021 | Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection | Company announcement – No. 41/ 2021
Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection ZEGALOGUE now available in both an auto-injector and prefilled syringe for the treatment of severe hypoglycemia... |
| 21.06.2021 | SYNEOS HEALTH, INC.
Syneos Health Accelerates Decentralized Clinical Trial Delivery, Unveils New Collaboration with Site Sponsors | MORRISVILLE, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today expanded its Decentralized Clinical Trial capabilities to include a dedicated Decen... |
| 16.06.2021 | ZEALAND PHARMA A/S
Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions | Company announcement – No. 39/2021
Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions
Company to present six abstracts on ZEGALOGUE® (dasiglucagon) injection... |
| 03.06.2021 | SYNEOS HEALTH, INC.
Syneos Health Launches Patient Voice Consortium | MORRISVILLE, N.C., June 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today launched its Patient Voice Consortium. The Consortium is a cross-functional hub des... |
| 03.06.2021 | SYNEOS HEALTH, INC.
Syneos Health Announces Pricing of Secondary Offering of Common Stock | MORRISVILLE, N.C., June 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced the pricing of the previously an... |
| 02.06.2021 | SYNEOS HEALTH, INC.
Syneos Health Announces Secondary Offering of Common Stock | MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced it commenced an underwritten sec... |
| 05.05.2021 | RIGEL PHARMACEUTICALS, INC.
Rigel Pharmaceuticals : Reports First Quarter 2021 Financial Results and Provides Business Update | SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2021, including sales of TAVALISSE® (fostamatinib disodium hexahydrat... |
| 04.05.2021 | SYNEOS HEALTH, INC.
Syneos Health Announces Pricing of Secondary Offering of Common Stock | MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced the pricing of the previously ann... |
| 03.05.2021 | SYNEOS HEALTH, INC.
Syneos Health Announces Secondary Offering of Common Stock | MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced it commenced an underwritten seco... |
| 13.04.2021 | RIGEL PHARMACEUTICALS, INC.
Rigel Pharmaceuticals : Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19 | SOUTH SAN FRANCISCO, Calif., April 13, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced positive topline results from a multi-center, Phase 2 clinical trial to evaluate the safety of fostamatinib, its oral sp... |
| 07.04.2021 | RIGEL PHARMACEUTICALS, INC.
Rigel Pharmaceuticals : Announces Closing of Strategic Collaboration with Lilly | SOUTH SAN FRANCISCO, Calif., April 7, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the successful closing of its license agreement with Eli Lilly and Company (Lilly), following the expiration of the waitin... |
| 29.03.2021 | SYNEOS HEALTH, INC.
Syneos Health Partners with Science 37® to Transform Clinical Trials – Increasing Speed and Diversity | MORRISVILLE, N.C. and LOS ANGELES, March 29, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Science 37, the industry’s only Decentralized Clinical Trial Operati... |
